Free Trial

Chemed (CHE) Competitors

Chemed logo
$447.32 +5.08 (+1.15%)
Closing price 03:59 PM Eastern
Extended Trading
$443.72 -3.60 (-0.80%)
As of 06:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CHE vs. MEDP, LH, DGX, DVA, CRVL, AMED, MD, AMN, CCRN, and EHC

Should you be buying Chemed stock or one of its competitors? The main competitors of Chemed include Medpace (MEDP), Labcorp (LH), Quest Diagnostics (DGX), DaVita (DVA), CorVel (CRVL), Amedisys (AMED), Pediatrix Medical Group (MD), AMN Healthcare Services (AMN), Cross Country Healthcare (CCRN), and Encompass Health (EHC).

Chemed vs. Its Competitors

Medpace (NASDAQ:MEDP) and Chemed (NYSE:CHE) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations.

Medpace has higher earnings, but lower revenue than Chemed. Chemed is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medpace$2.11B6.54$404.39M$13.4536.49
Chemed$2.43B2.68$302M$19.4523.00

Medpace has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500. Comparatively, Chemed has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500.

Medpace has a net margin of 18.74% compared to Chemed's net margin of 11.56%. Medpace's return on equity of 67.66% beat Chemed's return on equity.

Company Net Margins Return on Equity Return on Assets
Medpace18.74% 67.66% 21.86%
Chemed 11.56%25.83%17.77%

Medpace currently has a consensus target price of $422.27, suggesting a potential downside of 13.96%. Chemed has a consensus target price of $578.50, suggesting a potential upside of 29.33%. Given Chemed's stronger consensus rating and higher probable upside, analysts clearly believe Chemed is more favorable than Medpace.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Medpace
3 Sell rating(s)
11 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
1.94
Chemed
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Medpace had 1 more articles in the media than Chemed. MarketBeat recorded 22 mentions for Medpace and 21 mentions for Chemed. Medpace's average media sentiment score of 1.27 beat Chemed's score of 1.17 indicating that Medpace is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Medpace
16 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Chemed
14 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Positive

78.0% of Medpace shares are owned by institutional investors. Comparatively, 95.9% of Chemed shares are owned by institutional investors. 20.3% of Medpace shares are owned by company insiders. Comparatively, 3.3% of Chemed shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Medpace beats Chemed on 10 of the 16 factors compared between the two stocks.

Get Chemed News Delivered to You Automatically

Sign up to receive the latest news and ratings for CHE and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CHE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CHE vs. The Competition

MetricChemedMED IndustryMedical SectorNYSE Exchange
Market Cap$6.52B$5.39B$5.69B$21.37B
Dividend Yield0.54%1.28%5.72%3.49%
P/E Ratio23.0028.6075.8629.83
Price / Sales2.68162.97489.9288.60
Price / Cash17.3626.8725.8118.13
Price / Book6.024.4612.844.58
Net Income$302M$189.47M$3.28B$998.53M
7 Day Performance-3.37%-2.58%0.22%1.07%
1 Month Performance0.52%1.63%4.61%4.41%
1 Year Performance-22.74%13.58%68.33%14.45%

Chemed Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CHE
Chemed
4.9986 of 5 stars
$447.32
+1.1%
$578.50
+29.3%
-23.0%$6.44B$2.43B21.5815,695Positive News
Short Interest ↓
MEDP
Medpace
4.308 of 5 stars
$492.09
+1.0%
$412.73
-16.1%
+41.2%$13.68B$2.11B36.595,900Positive News
LH
Labcorp
4.6494 of 5 stars
$276.99
-0.6%
$290.33
+4.8%
+24.5%$23.16B$13.01B30.5770,000Positive News
DGX
Quest Diagnostics
4.7736 of 5 stars
$182.53
-0.5%
$186.00
+1.9%
+17.1%$20.52B$9.87B21.8656,000Positive News
DVA
DaVita
4.6494 of 5 stars
$134.44
-2.5%
$164.00
+22.0%
-19.9%$9.86B$12.82B13.2276,000Analyst Upgrade
CRVL
CorVel
2.0573 of 5 stars
$90.34
+5.7%
N/A-21.6%$4.39B$918.58M46.575,075High Trading Volume
AMED
Amedisys
2.0446 of 5 stars
$101.01
+0.0%
$100.50
-0.5%
+4.2%$3.32B$2.40B39.3020,000
MD
Pediatrix Medical Group
2.3479 of 5 stars
$16.95
-0.7%
$16.79
-1.0%
+51.5%$1.49B$2.01B13.144,305Analyst Downgrade
AMN
AMN Healthcare Services
4.6292 of 5 stars
$20.97
+0.6%
$28.25
+34.7%
-61.4%$799.06M$2.98B-2.702,968Short Interest ↓
CCRN
Cross Country Healthcare
3.5862 of 5 stars
$14.05
-0.4%
$17.93
+27.6%
-7.1%$461.94M$1.34B-54.048,205Positive News
EHC
Encompass Health
4.8023 of 5 stars
$125.93
+0.3%
$134.00
+6.4%
+33.6%$12.65B$5.37B24.6440,000Positive News
Analyst Forecast
Short Interest ↑

Related Companies and Tools


This page (NYSE:CHE) was last updated on 9/16/2025 by MarketBeat.com Staff
From Our Partners